Aurobindo Pharma moves up on acquiring 80% stake in Tergene Biotech
Aurobindo Pharma is currently trading at Rs. 1063.50, up by 5.55 points or 0.52% from its previous closing of Rs. 1057.95 on the BSE.
The scrip opened at Rs. 1066.55 and has touched a high and low of Rs. 1069.35 and Rs. 1037.20 respectively. So far 5391 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1592.55 on 13-Sep-2024 and a 52 week low of Rs. 985.00 on 13-Mar-2024.
Last one week high and low of the scrip stood at Rs. 1126.80 and Rs. 1037.20 respectively. The current market cap of the company is Rs. 62035.42 crore.
The promoters holding in the company stood at 51.82%, while Institutions and Non-Institutions held 41.49% and 6.69% respectively.
Aurobindo Pharma has completed the acquisition of entire 80% of the equity share capital of Tergene Biotech, a step-down subsidiary of the Tergene and also a joint venture company, held by Auro Vaccines, a wholly owned stepdown subsidiary of the Aurobindo Pharma. The purchase consideration is of Rs 10.76 crore. Post this transaction, Tergene has become a direct subsidiary of the company.
Earlier on February 6, 2025, the company’s board had approved to purchase entire 80% of the equity share capital of Tergene Biotech.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
